Needham analyst Mike Matson reiterated a Hold rating on ResMed (NYSE: RMD).The analyst commented: 'RMD is acquiring of Noctrix Health ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments